Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?

Código QR

Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?

Guardado en:

Detalles Bibliográficos
Autores principales:	Ahmed Donia, Ramla Shahid, Muhammad Nawaz, Tahir Yaqub, Habib Bokhari
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2ecd9f51bbf54eb393b7c8f7ccb6947e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Challenging clinical and organizational scenarios in cardiovascular diseases during the SARS-CoV-2 pandemic in Poland. Can we do better?
por: Wojciech Wojakowski, et al.
Publicado: (2020)

COVID-19 and SARS-CoV-2: Everything we know so far – A comprehensive review
por: Naz Sumaira, et al.
Publicado: (2021)

How we prepared our operating theatre for patients with SARS-CoV-2 virus
por: Justyna Rymarowicz, et al.
Publicado: (2020)

Can Science Help Resolve the Controversy on the Origins of the SARS-CoV-2 Pandemic?
por: Arturo Casadevall, et al.
Publicado: (2021)

Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
por: Phil-Robin Tepasse, et al.
Publicado: (2021)

The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
por: Thushan I. de Silva, et al.
Publicado: (2021)

Organ-specific genome diversity of replication-competent SARS-CoV-2
por: Jolien Van Cleemput, et al.
Publicado: (2021)

Considering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist
por: Andrew MK, et al.
Publicado: (2021)

Can the SARS-CoV-2 Spike Protein Bind Integrins Independent of the RGD Sequence?
por: Christopher A. Beaudoin, et al.
Publicado: (2021)

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
por: Emmanuel Faure, et al.
Publicado: (2014)

Coronavirus (SARS-CoV-2): Preventions, keys to diagnosis and treatment of SARS-CoV-2
por: Kuldeep Singh Patel, et al.
Publicado: (2020)

Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections
por: Liu T, et al.
Publicado: (2021)

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
por: Indrė Kučinskaitė-Kodzė, et al.
Publicado: (2021)

Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.
por: Morgane Rolland, et al.
Publicado: (2021)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Timothy Kottke, et al.
Publicado: (2021)

Testing for SARS-CoV-2
por: Popadić Dušan
Publicado: (2021)

SARS-CoV-2 in cardiomyocytes
por: Josef Finsterer
Publicado: (2021)

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.
por: Antonio Muruato, et al.
Publicado: (2021)

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
por: Antonio Muruato, et al.
Publicado: (2021)

Case Report: SARS-CoV-2 Infection—Are We Redeemed? A Report of Candida Spondylodiscitis as a Late Complication
por: Luis Miguel Moreno-Gómez, et al.
Publicado: (2021)

Oncolytic Virotherapy

Oncolytic Virotherapy
Publicado: (2016)

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
por: Aljawharah Alrubayyi, et al.
Publicado: (2021)

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
por: Margherita Passariello, et al.
Publicado: (2021)

Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques
por: Wei Deng, et al.
Publicado: (2020)

Are We Overdoing It? Changes in Diagnostic Imaging Workload during the Years 2010–2020 including the Impact of the SARS-CoV-2 Pandemic
por: Mateusz Winder, et al.
Publicado: (2021)

Mechanisms of Immunothrombosis by SARS-CoV-2
por: María Teresa Hernández-Huerta, et al.
Publicado: (2021)

Hotspot Mutations in SARS-CoV-2
por: Indrajit Saha, et al.
Publicado: (2021)

Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs.
por: Les Jones, et al.
Publicado: (2021)

Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity
por: Hagit Achdout, et al.
Publicado: (2021)

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
por: Xiuyuan Ou, et al.
Publicado: (2020)

Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers
por: Cucunawangsih Cucunawangsih, et al.
Publicado: (2021)

SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP
por: José Zúñiga, et al.
Publicado: (2021)

Morphometry of SARS-CoV and SARS-CoV-2 particles in ultrathin plastic sections of infected Vero cell cultures
por: Michael Laue, et al.
Publicado: (2021)

A mathematical model for the dynamics of SARS-CoV-2 virus using the Caputo-Fabrizio operator
por: Tahir Khan, et al.
Publicado: (2021)

Can a Nasal/Oral/Ocular Spray Inactivate and Prevent SARS-CoV-2 infection? A hypothesis
por: Fuentes,Edgardo, et al.
Publicado: (2020)

The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
por: Kyle M. Pierce, et al.
Publicado: (2021)

Author Correction: Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
por: Jianbo Dong, et al.
Publicado: (2021)

Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers
por: Maria Teresa Pagano, et al.
Publicado: (2021)

SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines
por: Palaniyandi Velusamy, et al.
Publicado: (2021)